A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 1, 2005, Pages 45-49

  Gatta, L ^a   Zullo, A ^b   Perna, F ^a   Ricci, C ^a   De Francesco, V ^c   Tampieri, A ^a   Bernabucci, V ^a   Cavina, M ^a   Hassan, C ^b   Ierardi, E ^c   Morini, S ^b   Vaira, D ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c 'Riuniti' Hospital   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG EVALUATION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 21744463045     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02522.x     Document Type: Article

References (30)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; I: 1273-5.
2. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997; 41: 8-13.
3. Proceedings of the American Digestive Health Foundation International Update Conference on Helicobacter pylori. McLean, VA. USA: February 13-16, 1997.
4. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
5. Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Can J Gastroenterol 1999; 13: 213-7.
6. Coelho LG, Leon-Barua R. Quigley EMM and Representatives of the Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Latin-American Consensus Conference on Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 2688-91.
7. Malfertheiner P, Megraud F, O'morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 1671-80.
8. Janssen MJ, Van Oijen AHAM, Verbeek ALM, Jansen JBMJ, de Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitromidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
9. Penston JG, McColl Kel. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43.
10. Georgopoulos DS, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16: 569-75.
11. Gisbert JP, Gisbert JL, Marcos S, et al. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-6.
12. Zullo A, Hassan C, Campo SMA, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001; 15: 1193-7.
13. Perri F, Festa V, Clemente R, et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
14. Isakov V, Domareva I, Koudryavtseva L, et al. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-82.
15. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
16. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: the updated Sydney System. Am J Surg Pathol 1996; 20: 1161-81.
17. Gene E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003; 17: 1137-43.
18. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
19. Gomollon F, Sicilia B, Duconos JA, et al. Third line treatment for Helicobacter pylori: a prospective, cultured-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2001; 15: 1543-7.
20. Perri F, Festa V, Clemente R, et al. Randomised study of two rescue therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
21. Perri F, Festa V, Clemente R, et al. A rifabutin-based rescue therapy for Helicobacter pylori-infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
22. Canducci F, Ometti V, Pola P, et al. Rifabutin-based Helicobacter pylori eradication rescue therapy. Aliment Pharmacol Ther 2001; 15: 143.
23. Fakheri H, Merat S, Hosseini V, et al. Low-dose furazolidone in triple therapy and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 89-93.
24. Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidones, quinupristin/ dalfopristin and new quinolones. J Antimicrob Chemother 2000; 46: 283-5.
25. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 46: 283-5.
26. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin-based triple regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002; 14: 1309-12.
27. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-40.
28. Best L, Cooper-Lesins G, Haldane D, et al. Helicobacter pylori antibiotic resistance in Canadian populations. Gastroenterology 2004; 126: S1293.
29. Cabrata J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
30. Cammarota G, Martino A, Dirozzi G, et al. High efficacy of 1 week doxycicline and amoxicillin-based quadruple regimen in a cultured-guided, third-line treatment approach. Aliment Pharmacol Ther 2004; 19: 789-95.